PRLD ▲ +0.5% - Prelude Therapeutics Incorporated $PRLD - Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer 13-OCT-2026 07:01 AM ET